Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-26T19:54:06.004Z Has data issue: false hasContentIssue false
  • English
  • Français

The Use of Live Attenuated Influenza Vaccine (LAIV) in Healthcare Personnel (HCP): Guidance from the Society for Healthcare Epidemiology of America (SHEA)

Published online by Cambridge University Press:  02 January 2015

Thomas R. Talbot ,
Hilary Babcock ,
Deborah Cotton ,
Lisa L. Maragakis ,
Gregory A. Poland ,
Edward J. Septimus ,
Michael L. Tapper ,
David J. Weber  and
SHEA Task Force on Healthcare Personnel Influenza Vaccination
Thomas R. Talbot*
Affiliation:
Departments of Medicine and Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
Hilary Babcock
Affiliation:
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
Deborah Cotton
Affiliation:
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts
Lisa L. Maragakis
Affiliation:
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Gregory A. Poland
Affiliation:
Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
Edward J. Septimus
Affiliation:
Hospital Corporation of America, Nashville, Tennessee Texas A&M Health Science Center, Bryan, Texas
Michael L. Tapper
Affiliation:
Lenox Hill Hospital and the New York, University School of Medicine, New York, New York
David J. Weber
Affiliation:
Departments of Medicine and Pediatrics, University of North Carolina, Chapel Hill, North Carolina
*
A-2200 Medical Center North 1161 21st Avenue South, Vanderbilt University Medical Center, Nashville, TN 37232 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Because of the live viral backbone of live attenuated influenza vaccine (LAIV), questions have arisen regarding infection control precautions and restrictions surrounding its use in healthcare personnel (HCP). This document provides guidance from the Society for Healthcare Epidemiology of America regarding use of LAIV in HCP and the infection control precautions that are recommended with its use in this population.

Infect Control Hosp Epidemiol 2012;33(10):981-983

Type
Shea Guidance Statement
Information
Infection Control & Hospital Epidemiology , Volume 33 , Issue 10 , October 2012 , pp. 981 - 983
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Centers for Disease Control and Prevention. Influenza vaccination coverage among health-care personnel: United States, 2010–11 influenza season. MMWR Morb Mortal Wkly Rep 2011;60(32):1073–1077.Google Scholar
2.Centers for Disease Control and Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone High-Dose) and guidance for use: United States, 2010. MMWR Morb Mortal Wkly Rep 2010;59(16):485–486.Google Scholar
3.Fluzone Intradermal (influenza virus vaccine): facts at a glance. http://multivu.prnewswire.com/mnr/sanofipasteur/49833/docs/49833-Fluzone_ID_Fact_Sheet.pdf. Accessed May 22, 2012.Google Scholar
4.Greenberg, DP, Robertson, C, Talbot, HK, Decker, MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine (QIV) containing two A and two B strains among persons ≥65 years of age. Paper presented at: 49th Annual Meeting of the Infectious Diseases Society of America, 21 October 2011; Boston, MA. https://idsa.confex.com/idsa/2011/webprogram/Paper31024.html. Accessed May 22, 2012.Google Scholar
5.Gregersen, JP, Schmitt, HJ, Trusheim, H, Broker, M. Safety of MDCK cell culture-based influenza vaccines. Future Microbiol 2011;6(2):143–152.CrossRefGoogle ScholarPubMed
6.Monto, AS, Ohmit, SE, Petrie, JG, et al.Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009;361(13):1260–1267.CrossRefGoogle ScholarPubMed
7.Belshe, RB, Edwards, KM, Vesikari, T, et al.Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356(7):685–696.CrossRefGoogle ScholarPubMed
8.Block, SL, Yogev, R, Hayden, FG, Ambrose, CS, Zeng, W, Walker, RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008;26(38):4940–4946.CrossRefGoogle ScholarPubMed
9.Hammitt, LL, Bartlett, JP, Li, S, et al.Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine.Vacane 2009;27(52):7359–7366.Google ScholarPubMed
10.Tosh, PK, Boyce, TG, Poland, GA. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc 2008;83(1):77–84.CrossRefGoogle ScholarPubMed
11.Fiore, AE, Shay, DK, Broder, K, et al.Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-8):1–52.Google ScholarPubMed
12.Vesikari, T, Fleming, DM, Aristegui, JF, et al.Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006;118(6):2298–2312.CrossRefGoogle ScholarPubMed
13.Pearson, ML, Bridges, CB, Harper, SA. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-2):1–16.Google ScholarPubMed
14.Centers for Disease Control and Prevention. Additional information about vaccination of specific populations: persons who live with or care for persons at higher risk for influenza-related complications, http://www.cdc.gov/flu/professionals/acip/specificpopulations.htm. Accessed August 24, 2012.Google Scholar
15.Levin, MJ, Song, LY, Fenton, T, et al.Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008;26(33):4210–4217.CrossRefGoogle ScholarPubMed
16.King, JC Jr, Treanor, J, Fast, PE, et al.Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000;181(2):725–728.CrossRefGoogle ScholarPubMed
17.Gorse, GJ, O'Connor, TZ, Young, SL, et al.Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003;21(17-18):2133–2144.CrossRefGoogle ScholarPubMed
18.Carr, S, Allison, KJ, Van De Velde, LA, et al.Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 204(10):1475–1482.CrossRefGoogle Scholar
19.Jackson, LA, Holmes, SJ, Mendelman, PM, Huggins, L, Cho, I, Rhorer, J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17(15-16):1905–1909.CrossRefGoogle ScholarPubMed
20.Hernandez, L. Hospitals shun H1N1 FluMist vaccine, wait for injections. October 6, 2009. http://www.thedenverchannel.com/news/21212055/detail.html. Accessed June 6, 2012.Google Scholar